Insulet Corporation achieved solid financial results in Q4 2024, reporting revenue of $597.5 million, up 17.2% YoY. The company's Omnipod revenue saw strong growth both in the U.S. and internationally. Adjusted EPS was $1.15, and free cash flow improved significantly. Gross margin increased to 72.1%.
Q4 2024 revenue grew 17.2% YoY to $597.5 million.
Omnipod revenue rose 16.9%, with international Omnipod revenue up 33.5%.
Adjusted EPS was $1.15, down from $1.40 in the prior year.
Free cash flow increased to $305.4 million, compared to $70.1 million last year.
Insulet expects revenue growth of 16%-20% for FY 2025, driven by continued Omnipod expansion and international growth, despite anticipated declines in drug delivery revenue.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance